enGene Holdings Management
Management criteria checks 0/4
enGene Holdings' CEO is Ron Cooper, appointed in Jul 2024, has a tenure of 1.5 years. total yearly compensation is $8.95M, comprised of 2.2% salary and 97.8% bonuses, including company stock and options. directly owns 0.015% of the company’s shares, worth $87.31K. The average tenure of the management team and the board of directors is 1.3 years and 2.6 years respectively.
Key information
Ron Cooper
Chief executive officer
US$8.9m
Total compensation
| CEO salary percentage | 2.20% |
| CEO tenure | 1.5yrs |
| CEO ownership | 0.01% |
| Management average tenure | 1.3yrs |
| Board average tenure | 2.6yrs |
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Oct 31 2025 | n/a | n/a | -US$117m |
| Jul 31 2025 | n/a | n/a | -US$95m |
| Apr 30 2025 | n/a | n/a | -US$80m |
| Jan 31 2025 | n/a | n/a | -US$69m |
| Oct 31 2024 | US$9m | US$197k | -US$55m |
Compensation vs Market: Ron's total compensation ($USD8.95M) is above average for companies of similar size in the US market ($USD2.29M).
Compensation vs Earnings: Insufficient data to compare Ron's compensation with company performance.
CEO
Ron Cooper (62 yo)
Mr. Ronald H. W. Cooper, also known as Ron, is Chief Executive Officer & Director of enGene Holdings Inc. from July 22, 2024 and serves as its President since October 21, 2024. Mr. Cooper is Independent Di...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 1.5yrs | US$8.95m | 0.015% $ 87.3k | |
| Co-Founder & Chief Scientific Officer | 27yrs | US$341.75k | 0.15% $ 898.1k | |
| CFO & Head of Business Development | 2.2yrs | no data | no data | |
| Chief Strategy & Operations Officer | 2.2yrs | US$1.03m | 0.42% $ 2.4m | |
| Chief Technology Officer | 1.3yrs | no data | no data | |
| Chief Legal Officer & Corporate Secretary | 2yrs | no data | 0% $ 0 | |
| Senior VP of Human Resources | 1.1yrs | no data | no data | |
| Chief Regulatory Officer | 1.1yrs | no data | 0.011% $ 65.5k | |
| Chief Development Officer | 1.1yrs | no data | no data | |
| Chief Global Commercialization Officer | less than a year | no data | no data | |
| Chief Medical Officer | less than a year | no data | no data |
Experienced Management: ENGN's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 1.5yrs | US$8.95m | 0.015% $ 87.3k | |
| Independent Director | 2.1yrs | US$684.87k | 0% $ 0 | |
| Member of Advisory Board | no data | no data | no data | |
| Independent Chairman | 2.8yrs | US$208.49k | 0.037% $ 215.4k | |
| Independent Director | 2.4yrs | US$197.75k | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | 19.3yrs | no data | no data | |
| Member of Clinical Advisory Board | 14yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Chairman of Scientific Advisory Board | no data | no data | no data | |
| Observer | no data | no data | no data |
Experienced Board: ENGN's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/06 09:10 |
| End of Day Share Price | 2026/01/06 00:00 |
| Earnings | 2025/10/31 |
| Annual Earnings | 2025/10/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
enGene Holdings Inc. is covered by 12 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jie Cheng | CGS International |
| Silvan Tuerkcan | Citizens JMP Securities, LLC |
| Michael Schmidt | Guggenheim Securities, LLC |